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Cholangiopathies are a diverse group of progressive diseases whose primary cell targets are cholangiocytes. To identify shared pathogenesis and molecular connectivity among the three main human cholangiopathies (biliary atresia [BA] , primary biliary cholangitis [PBC] , and primary sclerosing cholangitis [PSC]), we built a comprehensive platform of published data on gene variants, gene expression, and functional studies and applied network-based analytics in the search for shared molecular circuits. Mining the data platform with largest connected component and interactome analyses, we validated previously reported associations and identified essential and hub genes. In addition to disease-specific modules, we found a substantial overlap of disease neighborhoods and uncovered a group of 34 core genes that are enriched for immune processes and abnormal intestine/hepatobiliary mouse phenotypes. Within this core, we identified a gene subcore containing signal transduction and activator of transcription 3, interleukin-6, tumor necrosis factor, and forkhead box P3 prominently placed in a regulatory connectome of genes related to cellular immunity and fibrosis. We also found substantial gene enrichment in the advanced glycation endproduct/receptor for advanced glycation endproducts (RAGE) pathway and showed that RAGE activation induced cholangiocyte proliferation. Conclusion: Human cholangiopathies share pathways enriched by immunity genes and a molecular connectome that links different pathogenic features of BA, PBC, and PSC. (HEPATOLOGY 2018;67:676-689).
A lthough cholangiocytes are the primary target of injury in biliary syndromes, the location of injured cholangiocytes along the anatomical domains is one of the distinguishing features among the three primary cholangiopathies. The anatomical sites of injury obey a reproducible pattern focused predominantly either on intrahepatic bile ducts (as observed in primary biliary cholangitis [PBC] ), extrahepatic ducts and intrahepatic bile ducts (as in primary sclerosing cholangitis [PSC] ), or extrahepatic bile ducts with secondary involvement of intrahepatic cholangiocytes (as in biliary atresia [BA] ). The anatomical continuity and functional integrity of intra-and extrahepatic bile ducts are key to the homeostasis of bile production, modification, and excretion. (1, 2) If any of these functions are disrupted by genetic defects or injuries to cholangiocytes, bile flow is impaired and associated with disease phenotypes. (3) (4) (5) Clinically, they manifest as diverse cholangiopathies that often progress to cirrhosis and account for 16% of all liver transplants performed in the United States. (6) BA is a severe neonatal cholangiopathy characterized by a progressive fibroinflammatory obstruction of extrahepatic bile ducts in children with estimated frequency of 1 in 15,000 live births in the United States. (7) In contrast, PBC has a higher frequency of nearly 4 per 10,000 people, of which >90% are women, with a mean age of 55 years at diagnosis. (6, 8) Different than the other two cholangiopathies, PSC affects children and adults with a frequency as high as 1.62 in 10,000 people, a male predominance, and a median age of 30-40 years at diagnosis. (6, 8) Despite these age-and anatomy-related features and heterogeneity in clinical presentation, growing evidence points to a potential commonality in pathogenic mechanisms that involve the innate and adaptive immune systems, cholangiocyte damage and proliferation, accumulation of potentially toxic bile acids, and recruitment of neighboring cells in the reparative response. (3) (4) (5) Recent advances from patient-based studies examining the genome and liver transcriptome identified several genes, gene groups, and pathways linked to the pathogenesis of individual cholangiopathies. (9) (10) (11) For example, genome-wide association studies (GWAS) reported genetic associations of adducin 3 with BA, the interleukin (IL)-12/signal transduction and activator of transcription (STAT) 4 pathway with PBC, and the CD28/IL-2 pathway with PSC. (11) (12) (13) Based on the common cellular target and the continuity of the biliary epithelium within and outside the liver, we hypothesized that these cholangiopathies have common genes and gene groups that relate, at least in part, to shared pathogenic mechanisms of disease. To test this hypothesis, we applied comprehensive bioinformatics algorithms to published databases on gene sequence variants and tissue expression on BA, PBC, and PSC. We found that despite the signatures in each disease, they share gene groups and pathways highly enriched by immune response processes assembled into a biliary connectome containing a high degree of interaction networks. Within the networks, STAT3, IL6, tumor necrosis factor (TNF), and forkhead box P3 (FOXP3) have greater connectivity and, when combined with a high enrichment in the advanced glycation endproduct/receptor for advanced glycation endproducts (AGE-RAGE) pathway, they emerge as shared regulators of BA, PBC, and PSC.
Materials and Methods

DATABASE FOR CHOLANGIOPATHY-ASSOCIATED GENES
To collect information on genes associated with BA, PBC, and PSC, we curated genes from PubMed and DisGeNET (v4.0) databases (14) using the keywords "biliary atresia," "primary biliary cholangitis," or "primary biliary cirrhosis" (for PBC) and "primary sclerosing cholangitis" (for PSC). A gene was considered as associated with a cholangiopathy if it met at least one of the following criteria: (1) genetic association or mutation in one of the diseases; (2) functional association obtained from studies using experimental models; (3) differential expression in patients compared to controls; and (4) function as autoantigen by the encoded protein. These criteria identified disease-causing genes and genetic association with cholangiopathies, or captured genes that are involved in late-stage disease. We mapped the genes to human Entrez gene symbols and identification numbers. For GWAS studies, we set a threshold of P value <5 3 10 -8 (standard threshold) for PBC and PSC, and P value <1 3 10 -5 (suggestive threshold) for BA because of relatively small sample size of BA cohort in published studies. Genes associated with IHC (intrahepatic cholestasis) and PLD
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From the 1 The Liver Care Center and Divisions of Gastroenterology, Hepatology and Nutrition and (polycystic liver disease) were downloaded from DisGeNET (v4.0) databases. Detailed lists of diseaseassociated genes and overlapping genes are summarized in Supporting Tables S1 and S2.
MINING TOOLS AND DATABASES
We compiled multiple types of data including protein interactions, essential genes, and binding information for transcription factors and microRNAs (miRNAs) from literature and databases. Details for data mining methods and analytical approaches are provided in the Supporting Methods.
DYSREGULATED miRNAs IN CHOLANGIOPATHIES
To collect a set of common dysregulated miRNAs in cholangiopathies, we conducted a literature search for studies that assessed miRNAs dysregulation in cholangiopathies. Dysregulated miRNAs are defined as those that show differential expression between patients and healthy controls in published studies. A list of dysregulated miRNAs is summarized in Supplemental Table S7 .
BIOLOGICAL PROCESSES, MOUSE PHENOTYPE ENRICHMENT, AND KYOTO ENCYCLOPEDIA OF GENES AND GENOMES PATHWAY ANALYSES
Biological processes, mouse phenotype enrichment, and KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway analyses were performed using ToppFun tool in ToppGene Suite (https://toppgene. cchmc.org/) with core genes as input. (15) We used terms with Bonferroni corrected P value <0.05 for two-way CIMminer clustering with defaults settings.
STATISTICAL ANALYSES
The statistical significance of overlap between two gene lists in comparison with a genomic background was tested by Fisher's exact test using the GeneOverlap (version 1.10.0) R package. We performed 1,000 random permutations and calculated z-scores to test the significance of disease-associated gene localization and network-based disease separation S using methods/ Python scripts from Menche et al. (7) and transcription factor (TF)-miRNA feed-forward loops (FFLs) using in-house Python scripts (https://github.com/Zhenhualuo/TFs-miRNAs-Feed-Forward-Loop). Details for the calculation are provided in the Supporting Methods.
DATA VISUALIZATION
Venn diagrams were generated by Venny 2.1.0 (http://bioinfogp.cnb.csic.es/tools/venny/). Networks were visualized using Cytoscape (version 3.4.0) and bar graphs were created using GraphPad Prism 6 (GraphPad Software Inc., La Jolla, CA).
SCORING AND RANKING OF THE GENE SUBCORE
To provide a hierarchical ranking among the subcore genes, we applied a binary functional system that scores gene associations based on biological processes, involvement in abnormal liver and biliary function, report in studies of gene expression or sequence variants by GWAS, evaluation in experimental models, and relationship to clinical parameters. We defined "1" for association and "0" for no association. We summed all scores to generate a functional score for each gene. Then, connectivity scores were calculated by averaging the number of connections for each subcore genes from two connectomes. The overall scores were the sum of functional and connectivity scores.
CELL PROLIFERATION ASSAY AND REAL-TIME PCR
Human immortalized nonmalignant cholangiocyte H69 cells were cultured in 96-well plates (5,000 cells/ well). (16) After 24 hours, cells were cultured with Dulbecco's modified Eagle's medium/F-12 medium/0.5% serum 6 pretreatment with 5 ug/mL of recombinant human RAGE-Fc chimera (R&D, Minneapolis, MN) for 1 hour 6 100 ng/mL of recombinant human high mobility group box 1 (HMGB1; R&D, Minneapolis, MN) for 48 hours. Cellular proliferation was quantified with a colorimetric assay (CellTiter 96Aqueous; Promega, Madison, WI). RNA was isolated from H69 cells in different wells using the RNeasy Mini Kit (Qiagen, Valencia, CA) and subjected to real-time PCR with the Brilliant III SYBR Green QPCR Master Mix Gene Expression Assay Kit and the Mx3005p system (Stratagene, La Jolla, CA), normalized with glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Primer sequences are listed in Supporting Table S8 .
Results
BUILDING OF A DATABASE OF GENES ASSOCIATED WITH HUMAN CHOLANGIOPATHIES
To explore the existence of molecular pathways that are shared among the human cholangiopathies, we developed a systems biology analytical pipeline that started with manually curated lists of genes associated with BA, PBC, and PSC from PubMed and DisGe-NET databases (Fig. 1 ). DisGeNET is a comprehensive platform integrating information on human disease-associated genes and gene variants using the selection criteria described above. (14) After removal of duplication from different sources, we identified 276, 387, and 166 human genes associated with BA, PBC, and PSC, respectively (Supporting Table S1 ).
CHOLANGIOPATHY-ASSOCIATED GENES FORM DISEASE MODULES AND ENCODE HUB PROTEINS
Previous studies of the human interactome suggest that disease-associated proteins interact with one another and tend to cluster in the same neighborhood, forming a connected subgraph often referred to as a "disease module" (17) ; the disruption of a disease module results in a particular disease phenotype. To investigate whether the proteins encoded by the genes reported in studies of BA, PBC, and PSC form disease modules, we measured the size of the largest connected component (LCC) to quantify the degree to which the proteins tend to agglomerate. (17) Examining the significance of protein agglomeration, we also compared the observed LCC size with randomly permutated LCC sizes by computing z-scores, in which a threshold zscore 1.65 is larger than expected by chance at a P value <0.05. We found that the gene lists for each of the three diseases formed significantly connected disease modules, with observed LCC size z-scores of 10.6 for BA, 8.5 for PBC, and 19.1 for PSC ( Fig. 2A-C) .
To further analyze the functional relevance of genes in each disease, we applied predictive algorithms to determine whether they encode essential proteins and form hubs, as done in human interactome studies. (18, 19) Defining hubs by genes placed at the top 20% of nodes ranked by degrees in the human interactome and using an updated list of 3,326 essential genes, (19, 20) we found that each disease associated gene list significantly overlaps with hub genes or essential genes (all P value, <0.05; Supporting Table S9 ). Importantly, we found 43 genes (highlighted in red in Fig. 2D ) that overlap or are shared by at least two diseases that were also classified as hub genes (Fig. 2D ) and 43 genes (highlighted in red in Fig. 2E ) classified as essential genes. These data suggested that the changes in sequence or expression of the selected genes are predicted to disrupt important biological processes and may relate to disease phenotypes.
CHOLANGIOPATHIES HAVE OVERLAPPING DISEASE NEIGHBORHOODS
Another method to evaluate clinical and pathobiological similarities between two diseases is the network-based distance that is shared by the diseases, which is typically quantified as network-based Separation (or "S" 5 the mean shortest distances d AA and d BB within the respective cholangiopathies with the mean shortest distance d AB between their proteins). (17) In this approach, S>0 indicates that the two disease modules are topologically separated and are pathobiologically distinct, with S<0 indicating similarities. (17) Using this approach, we found that each cholangiopathy pair has a negative S and z-score <-1.65, indicating that they significantly overlap disease neighborhoods ( Fig. 3A-C) , thus supporting the premise that cholangiopathies share pathobiological and clinical similarities at the network level.
IDENTIFICATION OF CORE GENES THAT ARE SHARED BY BA, PBC, AND PSC
In order to identify genes that are shared among the primary cholangiopathies, we subjected the diseaseassociated genes listed in Supporting Table S1 to gene overlapping analysis using Fisher's exact test ( Fig. 3D ; Supporting Table S9 ). We found that several genes segregate with individual diseases or are shared by pairs of diseases, with a distinct group of 34 genes that are shared by all three cholangiopathies ( Fig. 3D ; Supporting Table S2 ), which we refer to as "core genes" (red colors in Fig. 3D ). These findings suggested that the three cholangiopathies share functionally related genes that may be linked to pathogenic mechanisms of disease.
CHOLANGIOPATHY CORE GENES ARE PREDOMINANTLY RELATED TO IMMUNITY
To explore whether the core genes may identify molecular pathways involved in pathogenic mechanisms of diseases, we studied biological and phenotypic properties of all 34 core genes. Enrichment analyses, using a right-tailed Fisher's exact test with Bonferroni correction of P < 0.05, revealed that the core genes were linked to 576 biological processes and 298 mouse phenotypes. Among these, responses to biotic stimuli, immune-related processes, and abnormal hepatobiliary/intestinal phenotypes comprised the top 10 highest levels of significance (Fig. 4A,B) , with additional enrichments for inflammation/immunity, and metabolism. Applying two-way CIMminer clustering analyses to investigate the functional relatedness of the core genes, we next analyzed the genes based on "biological processes" and uncovered a cluster of genes encoding the cytokines IL10, Toll-like receptor 4 (TLR4), TNFa, IL6, transforming growth factor beta 1 (TGFB1), and IL2 and the transcription factor, FOXP3 (Fig. 4C) . Analyzing the same group of core genes according to their relationships to "mouse phenotypes," we found a second cluster of genes encoding the same cytokines (IL10, TLR4, TNFa, IL6, TGFB1, and IL2) in addition to IL17A and prostaglandin-endoperoxide synthase 2 (PTGS2), and a new group with the transcription factors, nuclear factor kappa B subunit 1 (NFKB1), STAT3, tumor protein p53 (TP53), small mothers against decapentaplegic 3 (SMAD3), and hypoxia-inducible factor 1 (HIF1A; Fig. 4D ). These analyses pointed to a predominance of inflammation/immunity genes in the main core genes assigned to the cholangiopathies, and identified a highly connected immunity gene subcore containing 14 genes (TNF, IL10, FOXP3, TGFB1, IL2, IL17A, NFKB1, STAT3, TP53, SMAD3, HIF1A, PTGS2, IL6, and TLR4).
COREGULATORY NETWORK FOR TF-miRNA SUBCORE GENES
As an initial strategy to investigate how the immunity gene subcore may relate to shared pathogenic mechanisms of the three diseases, we searched for evidence of higher orders of regulation by miRNAs and TFs. There is increasing evidence that changes in the expression of TFs and miRNAs may lead to dysregulation of genes and encoded proteins involved in the pathogenesis of cholangiopathies. (21) (22) (23) (24) (25) In a first approach, we examined the FFL, an important element in regulatory networks (26) that can be classified into three types according to the master regulators: transcription factors FFL (TF-FFL), miRNAs FFL, and transcription factors-miRNAs composite FFL (TF-miRNA composite FFL). (27) In the coregulatory network, there were 5,575 TF-FFLs, 1,385 miRNAFFLs, and 332 TF-miRNA composite FFLs (Supporting Table S6 ). We then tested the significance of FFLs by comparing the observed number of FFLs with random permutated number of FFLs. Notably, all z-scores were larger than 1.65 (Fig. 5A-C) , suggesting that the observed FFLs in the set of transcription factors, miRNAs, and the subcore genes were significantly enriched. These data support a strong relatedness among the components of the immune subcore genes.
In the second approach, we used two-way CIMminer cluster analysis and found that the 14 genes can be grouped into two major gene classes based on TF regulation (Fig. 5D ). The first class comprised all cytokines, including IL6, TNF, IL10, IL17A, and IL2, whereas the second gene class contains mostly transcription factors, such as NFKB1 and STAT3 (Fig.  5D) , indicating that these genes can function as master regulators by integrating different signals coming from diverse pathways. However, we did not observe a similar regulatory pattern in the analysis of miRNAs (Fig. 5E) .
To further explore the potential regulation of miRNA-subcore genes in cholangiopathies, we curated a list of dysregulated miRNAs shared by the three diseases ( Fig. 5F ; Supporting Table S7 ). We found that only the miRNA hsa-miR-122-5p is shared by BA, PBC, and PSC (Fig. 5F , highlighted in red). All these data suggest that TFs are the master regulators in shared mechanisms of cholangiopathies, with a lessprominent presence of distinct miRNA profiles.
BUILDING A CONNECTOME FOR THE IMMUNE SUBCORE GENES
As a strategy to investigate how the immune subcore genes relate to one another, we next searched for an integrated model for the genes taking into account their biological roles (TFs or cytokines/chemokines) and their functional relatedness. Using TF-subcore regulatory information, we generated a three-disease immune subcore connectome that showed FOXP3, SMAD3, and NFKB1 in the periphery, with minimal relationship with the cytokines (Fig. 6A) . Most notably, STAT3, TP53, and HIF1A were centrally linked to all genes, among which STAT3 formed a node with the highest connectivity with a first level link to all genes except for TGFB1. Using the STRING database-v10 to generate a second immune subcore connectome, we found a higher frequency of level 1 connectivity for STAT3, FOXP3, TP53, and IL6 (Supporting Fig. S1 ).
Next, to identify which genes of the immune subcore have the highest level of shared association among the BA, PBC, and PSC, we performed an initial ranking of genes based on their combined involvement in several parameters, including biological and disease processes, involvement in abnormal liver and biliary processes, studies of gene expression or GWAS, evaluation in experimental models, and link to clinical parameters (Supporting Table S10 ). The genes with the highest level of shared association were TNF, IL2, IL6, TGFB1, FOXP3, and IL10 (functional scores, from Supplemental Table 10 ). Then, to develop a final rank of shared genes, we developed an overall score based on first-level connectivity (connectivity score; from Fig. 6A and Supporting Fig. S1 ) and functional studies (functional score, from Supporting Table S10 ).
As also shown in Supporting Table S10 (overall scores) , STAT3, IL6, TNF, and FOXP3 are among the top six genes encoding proteins related to inflammation/immunity. Analyzing these genes against all cholangiopathyassociated genes (from Supporting Table S1 ) and miRNAs (from Supporting Table S6 ), we found their relationships with genes that are shared by BA, PBC, and PSC, as well as with each disease separately, and a highest connectivity for STAT3 (Fig. 6B) . Last, to test the specificity and of the connectome to the three cholangiopathies, we examined whether the 34 core genes overlapped with the genes for the two disease controls IHC and PLD. Only ABCB11, ABCB4, HLA-DRB1, ABCC2, and NR1I2 genes were shared with IHC and none with PLD ( Supporting  Fig. S2A) ; these five genes are involved in bile acid metabolism and transport systems (Supporting Fig.  S2B,C) . Notably, the genes STAT3, IL6, TNF, and FOXP3 were not shared by IHC or PLD. These findings support the involvement of metabolism and transport systems as a shared process among all five cholestatic and biliary diseases analyzed. They also support the specificity of the connectome to the key biological processes of inflammation and fibrosis that are shared by BA, PBC, and PSC.
IDENTIFICATION OF RAGE IN HUMAN CHOLANGIOPATHIES
To generate insight into potential molecular mechanisms not previously linked to BA, PBC, or PSC, we subjected the connectome genes to KEGG pathway analysis. Six of 14 subcore genes (TGFB1, SMAD3, NFKB1, IL6, TNF, and STAT3) resided in the AGE-RAGE pathway, a less-characterized circuit that activates inflammatory and profibrogenic signaling (Fig.  7A) . The AGE-RAGE pathway was also enriched in genes signatures for each disease individually, to any combination of two of these diseases, and to TFs that regulate the 14 subcore genes, but not in genes associated with IHC and PLD (Fig. 7B) .
Exploring the potential biological relevance for the pathway, we tested whether the activation of AGE-RAGE influences cholangiocyte proliferation, a hallmark of cholangiopathies. (5) Culture of human cholangiocyte H69 cells with HMGB1 (a ligand for RAGE) for 48 hours increased cell proliferation by 3-fold, an effect that was abolished by the addition of recombinant human RAGE-Fc chimera protein to block the receptor (Fig. 7C) . Interestingly, the activation of this pathway also up-regulated mRNA expression for the biliary mitogen, IL6, and profibrogenic factor, TGFB1, but not other genes ( Fig. 7D and Supporting Fig. S3 ).
Discussion
Applying systems biology algorithms to a comprehensive data platform on gene variant and expression from patients with BA, PBC, and PSC, we found gene groups that form modules for each disease independently and that encode hub proteins. Among the genes, 34 formed a core shared by the three diseases and related to immune-regulated processes, abnormal hepatobiliary and intestinal function, and abnormal mouse phenotypes. Within this core, 14 genes were functionally connected and formed a subcore encoding proteins regulating immune processes and fibrosis, with two major functional classes of cytokines and transcription factors, and high level of connectivity based on relationships to transcription factors. Ranking the genes in this subcore according to composite scores for functional relatedness and links to the disease phenotypes, we generated a connectome shared by BA, PBC, and PSC, which contained STAT3, IL6, FOXP3, and TNF as key genes. Furthermore, pathway analyses identified the AGE-RAGE pathway in the cholangiopathies, with experimental evidence that activation of RAGE induces cholangiocyte proliferation and expression of IL6 and TGFB1. These data demonstrate that BA, PBC, and PSC share common molecular pathways predominantly linked to immunity and are linked to the AGE-RAGE pathway and other genes related to fibrosis.
The prominence of STAT3 and secondarily of IL6, FOXP3, and TNF in every analytical strategy applied to the data platform suggests essential roles of proinflammatory and anti-inflammatory circuits in biliary damage and repair. Both IL-6 and TNFa are expressed by cholangiocytes in response to an insult or injury (28) and may function in an autocrine and paracrine fashion to amplify the damage and or trigger repair signals. (28) IL-6 binding to its receptor on cholangiocyte activates STAT3 and mitogen-activated protein kinase signaling to promote cholangiocyte proliferation. (29) In parallel or independently, TNFa increases the expression of many proinflammatory cytokines, including IL-6 and major histocompatibility complex epitopes. (29, 30) If expressed concomitantly with interferon-gama, TNFa induces cholangiocyte apoptosis. (31) Moreover, TNFa and IL-6 regulate the immune response by modulating FOXP3 expression levels in T cells. (32) (33) (34) (35) (36) Combined, these studies support an inter-relatedness between STAT3, IL6, FOXP3, and TNF in cholangiocyte biology and pathogenesis of biliary injury in BA, PBC, and PSC. Evidence from human data and mouse models of cholangiopathies suggests that these four genes play a role in mechanisms of tissue injury and clinical phenotype. For example, the activation of the IL6-STAT3 pathway has been demonstrated in patients with BA, PBC, and PSC. (10, 37, 38) This pathway has been studied in experimental model of cholangiopathies. In BA, increased IL-6 levels are associated with cholangiocyte proliferation. (38) In PBC, the targeted disruption of the IL6 gene exacerbates cholangitis in the TGFb receptor II dominant-negative (dnTGFbetaRII) mouse model. (39) In PSC, the loss of functional Stat3 protects the liver from injury and fibrosis in the Mdr2 knockout mouse model. (40) In contrast to the IL6-STAT3 pathway, the role of TNFa in cholangiopathies is less explored and understood. TNFa is upregulated in liver of the experimental mouse model of BA, (41) but an earlier study showed that the constitutive inactivation of the TNFR1 gene, one of the TNFa receptors, failed to decrease the severity of experimental BA. (41) More recently, we reported that a preferential use of the TNFR2 by TNFa may be an important circuit that is more relevant to the pathogenesis of BA. (42) In PBC, increased TNFa levels were found in liver samples of patients, (37) whereas TNFA polymorphisms were associated with the risk of PSC. (43) TNFa has been shown to impair the function of liver-derived T cells and natural killer (NK) cells in PSC patients. (44) Regulatory T cells (Tregs) and their marker, FOXP3, have emerged as key regulatory components in BA, PBC, and PSC. FOXP3 expression levels were higher in livers of BA and PBC patients compared to normal controls, whereas decreased levels were observed in peripheral blood mononuclear cells from PBC patients. (34) (35) (36) In experimental BA, Foxp3
1 regulatory T cells inhibit T helper 1 cell-mediated injury and control dendritic celldependent NK-cell activation and CD8 T-cell response. (34, 45, 46) And, in PSC, CD25 high FOXP3 1
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low Treg cells were reduced in peripheral blood and livers of PSC patients and associated with IL2RA polymorphisms. (47) These data suggest that the dysregulation of the four key genes and their related cell types play important roles in the immune mechanisms of cholangiopathies. Interestingly, the similar behavior of FOXP3 and Treg cells in patients and experimental models of BA and PSC suggests a closer link of pathogenic mechanisms between these two diseases ( Table 1) .
Expression of RAGE was has been reported as higher in cholangiocytes when compared to other cell types in cholestatic livers (48) and in proliferating bile ducts after bile duct ligation, (49) where the administration of anti-RAGE antibodies attenuated bile duct proliferation and liver fibrosis. (50) This is particularly relevant to our findings of a connectome gene enrichment in the AGE-RAGE pathway. Directly testing this pathway in cholangiocytes, we showed that HMGB1, a damage-associated molecular pattern released from injured cells, (5) induces cholangiocyte proliferation and expression of IL6 and TGFB1 mRNAs through RAGE. These data raise several experimental opportunities to modulate the pathway in animal models of BA, PBC, and PSC in future preclinical studies to explore its potential as a therapeutic target for the cholangiopathies.
Among the limitations of our study, we recognize that there is an intrinsic bias toward well-studied genes that have been well annotated and extensively investigated, and that components of the gene signatures for individual diseases or the connectome may overlap with other unrelated diseases or be part of a stereotypical tissue (or cellular) response to an injury. In addition, the measures of significance vary among the studies, either focusing on differences in the frequency of gene variants or in the levels of expression in individual cholangiopathies, with limited information on how studies controlled for racial and sex differences. Last, the coregulation of the core immune genes by transcription factors and miRNAs are cell type and content dependent. Experimental validation is needed to determine their relevance to cholangiopathies. These limitations notwithstanding, our report of a connectome that generates a molecular link among the three human cholangiopathies of BA, PBC, and PSC underscores the existence of important roles and molecular cross-talks involving multiple immune signaling modules in the pathogenesis of the diseases. The connectome and network of TFs/miRNAs/core immune genes can serve as a valuable tool for hypothesis generation and enhance our understanding of regulatory mechanism of cholangiopathies.
